Africa’s Most Unexamined Health Crisis Is Getting New Attention — and New Funding
Neglected Tropical Diseases — a family of parasitic and bacterial infections that blight the lives of over 600,000 people every year, most of them in Africa — have long occupied the bottom rung of the global health priority ladder. But a new 200 million dollar vaccine development fund launched this week represents one of the most ambitious attempts to change that calculus. Coefficient Giving, the initiative behind the fund, says its mission is to accelerate development of a Strep A vaccine that could prevent hundreds of thousands of deaths that current tools simply cannot stop.
Strep A — Group A Streptococcus — is a bacterial infection that most people associate with sore throats and childhood illnesses in wealthy countries. But in sub-Saharan Africa and parts of South Asia, it is a silent killer that causes rheumatic heart disease, a condition that permanently damages the heart valves of young people and kills an estimated 500,000 people globally each year, the vast majority of them in low-income countries. There is no vaccine. There has been very little research investment. And for the people living with the consequences, the only options are expensive surgery or a slow decline into heart failure.
Why These Diseases Get Left Behind
The economics of vaccine development have always worked against neglected tropical diseases. Pharmaceutical companies invest where the return on research is clear and where regulatory markets are large and profitable. By that logic, diseases that predominantly affect poor people in remote rural areas are simply not worth the billions of dollars required to bring a new vaccine to market. The result is what global health advocates call a ‘fatal disparity’ — the people who bear the highest burden of infectious disease are the ones with the least capacity to drive investment in their own protection.
Coefficient Giving’s approach attempts to bridge that gap by pooling donor capital to make the financial case for research that would otherwise not happen. The 200 million dollar fund, which has already secured over 140 million dollars in commitments from a coalition of foundations and governments, will go directly to financing clinical trials for multiple promising vaccine candidates simultaneously — a portfolio approach designed to increase the odds that at least one candidate will succeed. Organisers say the goal is to compress a process that typically takes a decade or more into a five-year timeline.
What This Means for Africa
If the Strep A vaccine programme succeeds, it would mark one of the most significant wins for African health in the 21st century. Rheumatic heart disease is a condition that is entirely preventable with early antibiotic treatment — which is widely available in wealthy countries — but which in Africa often goes undetected until the damage to the heart is irreversible. A vaccine would eliminate the disease at its source, sparing hundreds of thousands of children and young adults from a lifetime of cardiac complications that they currently have almost no defence against.
The broader message behind the fund, however, extends beyond Strep A. Global health advocates have long argued that the system for setting research priorities is skewed against the diseases of the poor — and that fixing that distortion requires direct intervention in the market, not just appeals to corporate conscience. Coefficient Giving’s initiative is one of the most concrete attempts yet to prove that you can make neglected disease research commercially viable if you are willing to restructure the incentive. Whether it delivers on its promise will be watched closely in African health ministries, in the laboratories where the vaccines are being developed, and in the communities that have been waiting generations for a solution to diseases the world chose to forget.
